Yes, I think that's exactly it. We're quite excited about this progressive licensing, and we think it should be accompanied by progressive reporting. That's what we're talking about.
Report what you have to report. Then somebody at the other end will say, okay, this is the point where the flag goes up; we have to do something. So link that to progressive licensing, especially for use in children. You have to remember, children are in our system from age zero to 18. Well, the six-month-old doesn't need the same thing as the 13-year-old; and regarding the 17-and-a-half-year-old, where are you? So you have to be careful with that.
For off-label use for certain populations that have not been tested, or for certain uses that were never envisaged to begin with, physicians are smart; they will try something if they think it might have a beneficial effect for their patient. If they can feed that in quickly and usefully to a system that is monitoring all of that, we're quite in support of the progressive licensing.